Methods and compositions for identifying therapeutic...

Details Methods and compositions for identifying therapeutic... Methods and compositions for identifying therapeutic...

2007-09-25

2007-09-25

Gitomer, Ralph (Department: 1657)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving hydrolase

Reexamination Certificate

active

10970794

ABSTRACT:
By the present invention, enzymes responsible for prodrug activation are identified and utilized for the identification of candidate compounds as prodrugs. The present invention includes methods for identifying a candidate compound as a suitable prodrug as well as methods of screening candidate compounds for suitability as therapeutic agents.

REFERENCES:
patent: 5413996 (1995-05-01), Bodor
patent: 5670497 (1997-09-01), Bold et al.
patent: 5750343 (1998-05-01), Maag et al.
patent: 5750493 (1998-05-01), Sommadossi et al.
patent: 5874577 (1999-02-01), Chen et al.
patent: 5914332 (1999-06-01), Sham et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6319946 (2001-11-01), Hale et al.
patent: 6767900 (2004-07-01), Ubasawa et al.
patent: 2001/0031773 (2001-10-01), Camden
patent: 2002/0119443 (2002-08-01), Becker et al.
patent: 2003/0109498 (2003-06-01), Yuasa et al.
patent: 2004/0121316 (2004-06-01), Birkus et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 441 192 (1991-08-01), None
patent: 0 465 297 (1992-01-01), None
patent: 0 531 597 (1993-03-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 786 455 (1997-07-01), None
patent: 0 852 233 (1998-07-01), None
patent: 0 919 562 (1999-06-01), None
patent: 1 295 879 (2003-03-01), None
patent: WO88/06158 (1988-08-01), None
patent: WO91/19721 (1991-12-01), None
patent: WO92/00988 (1992-01-01), None
patent: WO92/18520 (1992-10-01), None
patent: WO93/12123 (1993-06-01), None
patent: WO93/24510 (1993-12-01), None
patent: WO96/14314 (1996-05-01), None
patent: WO96/40156 (1996-12-01), None
patent: WO97/15588 (1997-05-01), None
patent: WO98/04569 (1998-02-01), None
patent: WO98/11906 (1998-03-01), None
patent: WO99/62921 (1999-12-01), None
patent: WO 00/04033 (2000-01-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/17982 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/39724 (2001-06-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/64693 (2001-09-01), None
patent: WO 01/39724 (2001-10-01), None
patent: WO 01/96329 (2001-12-01), None
patent: WO 01/96354 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06292 (2002-01-01), None
patent: WO 02/08241 (2002-01-01), None
patent: WO 02/14344 (2002-02-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/103008 (2002-12-01), None
patent: WO 03/028737 (2003-04-01), None
patent: WO 03/050129 (2003-06-01), None
patent: WO 03/059255 (2003-07-01), None
patent: WO 03/064383 (2003-08-01), None
patent: WO 03/066005 (2003-08-01), None
patent: WO 03/080078 (2003-10-01), None
patent: WO 02/103008 (2003-11-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 2004/096234 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2005/011709 (2005-02-01), None
International Search Report for International Application No. PCT/US2004/035083.
Ballatore, C., et al., “Synthesis and Evaluation of Novel Amidate Prodrugs of PMEA and PMPA”,Bioorganic&Medicinal Chemistry Letters, Oxford, GB, vol. 11, 2001, pp. 1053-1056.
International Search Report for International Application No. PCT/US2004/035084.
International Search Report for International Application No. PCT/US2004/035085.
Siddiqui, A. Q., et al., “Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR”,Journal of Medicinal Chemistry, American Chemical Society, Washington, DC, vol. 42, No. 20, 1999, pp. 4122-4128.
Tan, Fulong, et al., “Sequencing and Cloning of Human Prolylcarboxypeptidase (Angiotensinase C): Similarity to Both Serine Carboxypeptidase and Prolylendopeptidase Families”,Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, vol. 268, No. 22, 1993, pp. 16631-16638.
Valette, G. et al., “Decomposition Pathways and in Vitro HIV Inhibitory Effects of IsoddA Pronucleotides: Toward a Rational Approach for Intracellular Delivery of Nucleoside 5′-Monophosphates”,Journal of Medicinal Chemistry, American Chemical Society, Washington, DC, vol. 39, No. 10, 1996, pp. 1981-1990.
Abdel-Meguid et al., “Inhibition of Human Immunodeficiency Virus-1 Protease by a C2-Symmetric Phosphinate. Synthesis and Crystallographic Analysis”,BioChemistry, 32(31):7972-7980 (1993).
Allen et al., “CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK)”,Seminars in Oncology, 30(5, Suppl. 16):105-116 (2003).
Andrade et al., “HIV-Related Drug Metabolism and Cytochrome P450 Enzymes”AIDS Clinical Care, 12(11):91-95 (2000).
Bantia et al., “Purine Nucleoside Phosphorylase Inhibitor BCX-1777 (Immucillin-H)—A Novel Potent and Orally Active Immunosuppressive Agent”,International Immunopharmacology, 1:1199-1210 (2001).
Beauchamp, et al., “Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase”,Journal of Medicinal Chemistry, 39:949-956 (1996).
Borhani et al., “A-420983: A Potent, Orally Active Inhibitor of lck with Efficacy in a Model of Transplant Rejection”,Bioorganic&Medicinal Chemistry Letters, 14:2613-2616 (2004).
Bzowska et al., “Purine Nucleoside Phosphorylases: Properties, Functions, and Clinical Aspects”,Pharmacology&Therapeutics, 88:349-425 (2000).
Chapman et al., “Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340”,Nucleosides, Nucleotides&Nucleic Acids, 20(4-7):621-628 (2001).
Charvet et al., “Inhibition of Human Immunodeficiency Virus Type I Replication by Phosphonoformate- and Phosphonoacetate-2′,3′-Dideoxy-3′-thiacytidine Conjugates”,Journal of Medicinal Chemistry, 37(14):2216-2223 (1994).
Clark et al., Abstract, “Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection”, Institute for Antiviral Research, Utah State University.
Conklyn et al., “The JAK3 Inhibitor CP-690550 Selectively Reduces NK and CD8+ Cell Numbers in Cynomolgus Monkey Blood Following Chronic Oral Dosing”,Journal of Leukocyte Biology, 76:1-8 (2004).
De Clercq, “Chemotherapy of Human Immunodeficiency Virus (HIV) Infection: Anti-HIV Agents Targeted at Early Stages in the Virus Replicative Cycle”,Biomedicine and Pharmacotherapy, 50(5):207-215 (1996).
De Clercq, “Highlights in the Development of New Antiviral Agents”,Mini Reviews in Medicinal Chemistry, 2(2):163-175 (2002).
De Clercq, “New Developments in Anti-HIV Chemotherapy”,Current Medicinal Chemistry, 8(13):1543-1572 (2001).
Dvo{hacek over (r)}áková et al., “Synthesis of 2′-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents”,J. Med. Chem.,39(17):3263-3268 (1996).
Eisenberg et al., “Metabolism of GS-7340, a Novel Phenyl Monophosphoramidate Intracellular Prodrug of PMPA, in Blood”,Nucleosides, Nucleotides&Nucleic Acids, 20(4-7):1091-1098 (2001).
Evans et al., “Exploring Structure—Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase”,J. Med. Chem.,46(15):3412-3423 (2003).
Gobec et al., Phosphonate Inhibitors of Antigen 85C, A Crucial Enzyme Involved in the Biosynthesis of theMycobacterium tuberculosisCell Wall,Bioorganic and Medicinal Chemistry Letters, 14:3559-3562 (2004).
Gorin et al., “A Novel Esterification Procedure Applied to Synthesis of Biologically Active Esters of Foscarnet”,Tetrahedron Letters, 38(16):2791-2794 (1997).
Gumina et al., “A

Affiliated with

Also associated with

Rating

Methods and compositions for identifying therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for identifying therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for identifying therapeutic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3755738